Weight-loss injections and life insurance underwriting: What advisers should know

The growing use of weight loss injections is increasingly influencing life insurance underwriting, particularly in cases involving obesity, recent weight change, and long-term health risk.

Treatments based on GLP-1 receptor agonists, such as semaglutide (including Wegovy and Ozempic), are now widely used for weight management, prompting insurers to reassess established approaches to BMI and risk assessment.

As uptake continues to rise, advisers involved in life insurance planning for high-net-worth individuals are encountering these considerations more frequently at the application stage.

Weight-loss injections in an underwriting context

GLP-1 medications were originally developed for Type 2 diabetes but are now approved for weight management in individuals with obesity or obesity-related metabolic conditions. Their effectiveness in supporting weight reduction has led to rapid adoption, though insurers remain cautious where weight loss is recent or medication use is ongoing.

Current market practice often involves underwriters “adding back” around 50% of any weight lost in the previous 12 months when calculating BMI, reflecting concerns around long-term sustainability.

How life insurers are currently approaching these cases

Life insurers are adapting underwriting frameworks as experience and data develop.

• Weight stability: Where medication has been discontinued and reduced weight has been maintained for at least six months, insurers are generally more comfortable treating the new weight as stable.
• Health markers: Improvements in blood pressure, cholesterol, and glucose control are recognised, though sustained outcomes are typically required before underwriting terms are adjusted.
• Comorbidities: Reductions in obesity-related conditions, such as Type 2 diabetes and cardiovascular risk factors, may influence underwriting outcomes over time.
• Clinical rationale: Insurers distinguish between clinically driven weight management and use that appears primarily cosmetic.

Access to medication and insurer perception

The method by which weight-loss injections are accessed can also influence underwriting.

• Medically supervised use: Private access to weight-loss medication does not generally raise concerns where treatment is overseen by a medical professional and supported by appropriate clinical records.
• Self-administration: Self-administration can be queried, particularly as NHS prescribing guidance restricts access to patients meeting strict obesity criteria.
• Online providers: While online services are increasingly common, insurers may assess the level of monitoring, follow-up, and dosage control involved.

Longer-term underwriting considerations

Although short-term outcomes are increasingly well understood, the long-term implications remain under review.

• Maintenance dosing: As long-term maintenance use becomes more common, insurers’ underwriting guidelines are expected to evolve as additional data becomes available.
• Side effects and relapse risk: Potential adverse effects and weight regain following treatment cessation continue to be factored into risk assessment.
• Behavioural risk: Some insurers are beginning to monitor the potential for excessive or prolonged use, particularly where patterns could resemble disordered eating behaviours.

Market monitoring and ongoing developments

At John Lamb Hill Oldridge, our specialist underwriting team actively monitors insurer responses and emerging underwriting trends in this area.

As weight-loss injections become more prevalent, insurer approaches are continuing to develop, with increasing differentiation between recent weight loss, stable outcomes, and long-term maintenance.

Conclusion

Weight-loss injections represent a developing area within life insurance underwriting. While current approaches remain cautious, particularly where weight loss is recent, underwriting frameworks are evolving as long-term evidence builds.

For advisers, understanding these trends is becoming an increasingly important part of navigating life insurance applications in a changing risk landscape.

Get in touch

At John Lamb Hill Oldridge, our advisers are experts in offering bespoke insurance that supports high-net-worth and ultra-high-net-worth clients in protecting their wealth.

For more information about how we can help you to support your clients, please get in touch. Email mail@jlho.co.uk or call us on 020 7633 2222.

Please note

This article is for general information only and does not constitute advice. The information is aimed at retail clients only.

All information is correct at the time of writing and is subject to change in the future.

The Financial Conduct Authority does not regulate estate planning or tax planning.

Note that financial protection plans typically have no cash in value at any time, and cover will cease at the end of the term. If premiums stop, then cover will lapse.

Cover is subject to terms and conditions and may have exclusions. Definitions of illnesses vary from product provider and will be explained within the policy documentation.

The Financial Conduct Authority does not regulate estate planning, cashflow planning or tax planning.